CIK 0001658551
- Non-accelerated filer
- Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464600503
- Phone
- +1 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- 4/A Open-market buy 10% owner bought 263,158 shares at $19.00 ($5,000,002)
- 3/A Insider 3/A
- 4 Grant or award Chief Legal Officer acquired 41,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 263,158 shares at $19.00 ($5,000,002)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy 10% owner bought 2,300,000 shares at $19.00 ($43,700,000)
- 3 Insider Initial Statement of Ownership
- 4 Open-market buy Director bought 3,947 shares at $19.00 ($74,993)
- 4 Open-market buy Director bought 6,578 shares at $19.00 ($124,982)
- 4 Grant or award Chief Medical Officer acquired 28,333 shares (grant or award)
- 4 Open-market buy Director bought 26,315 shares at $19.00 ($499,985)
- 4 Grant or award Co-Chief Executive Officer acquired 75,000 shares (grant or award)
- 4 Derivatives Options or other derivatives
- 4 Open-market buy Chief Commercial Officer bought 6,842 shares at $19.00 ($129,998)
- 4 Grant or award Chief Financial Officer acquired 31,667 shares (grant or award)
- 4 Grant or award Co-Chief Executive Officer acquired 75,000 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 10 of 11 · 207 filings